Literature DB >> 14743498

Expression of IL-27 in human Th1-associated granulomatous diseases.

Frédérique Larousserie1, Stefan Pflanz, Aurore Coulomb-L'Herminé, Nicole Brousse, Rob Kastelein, Odile Devergne.   

Abstract

Interleukin (IL)-27 is a newly described member of the IL-12 family. It is a heterodimeric cytokine composed of two subunits, p28 and Epstein-Barr virus-induced gene 3 (EBI3). In vitro studies have shown that IL-27 is mainly produced by activated monocytes and dendritic cells. It induces the proliferation of naïve CD4-positive T cells and synergizes with IL-12 for interferon-gamma (IFN-gamma) production. Knock-out mice for the IL-27 receptor (WSX-1/TCCR) have impaired Th1 responses and form abnormal granulomas when injected with bacillus Calmette-Guérin. However, the expression profile of IL-27 in vivo is currently unknown. To investigate the potential role of IL-27 in the development of a Th1 response in humans in vivo, this study has analysed the in situ expression of IL-27 subunits in three types of granulomatous disease (tuberculosis, sarcoidosis, and Crohn's disease), each characterized by a Th1 response. Tissue sections from patients with tuberculosis (n = 9), sarcoidosis (n = 8), or Crohn's disease (n = 7) were analysed by immunohistochemistry with anti-EBI3 and anti-p28 antibodies, in parallel with control tissues (control reactive lymph nodes, n = 14, and control intestinal tissues, n = 11). In granulomatous tissues, EBI3 and p28 co-expression was detected in epithelioid and multinucleate giant cells in granulomas. In addition, sinus or tissue macrophages, endothelial cells, and plasma cells were found to co-express EBI3 and p28. These data support a possible role for IL-27 in human Th1 responses. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14743498     DOI: 10.1002/path.1508

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  46 in total

1.  Osseous sarcoidosis: a case series.

Authors:  Halyna Kuzyshyn; David Feinstein; Sharon L Kolasinski; Hala Eid
Journal:  Rheumatol Int       Date:  2014-11-02       Impact factor: 2.631

Review 2.  Intestinal microvascular endothelium and innate immunity in inflammatory bowel disease: a second line of defense?

Authors:  Jan Heidemann; Wolfram Domschke; Torsten Kucharzik; Christian Maaser
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

Review 3.  Sarcoidosis--scientific progress and clinical challenges.

Authors:  Edward S Chen; David R Moller
Journal:  Nat Rev Rheumatol       Date:  2011-07-12       Impact factor: 20.543

4.  Suppression of TNF-α and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27.

Authors:  George D Kalliolias; Rachael A Gordon; Lionel B Ivashkiv
Journal:  J Immunol       Date:  2010-10-22       Impact factor: 5.422

5.  Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis.

Authors:  Stefan Wirtz; Ulrike Billmeier; Tamuna Mchedlidze; Richard S Blumberg; Markus F Neurath
Journal:  Gastroenterology       Date:  2011-08-04       Impact factor: 22.682

6.  EBI3 deficiency leads to diminished T helper type 1 and increased T helper type 2 mediated airway inflammation.

Authors:  Elif Dokmeci; Lan Xu; Eve Robinson; Kseniya Golubets; Kim Bottomly; Christina A Herrick
Journal:  Immunology       Date:  2011-01-24       Impact factor: 7.397

7.  IL-27 and type 2 immunity in asthmatic patients: association with severity, CXCL9, and signal transducer and activator of transcription signaling.

Authors:  Min Xie; Anthony T Mustovich; Yi Jiang; John B Trudeau; Anuradha Ray; Prabir Ray; Haizhen Hu; Fernando Holguin; Bruce Freeman; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2014-10-11       Impact factor: 10.793

8.  Transcriptional suppression of IL-27 production by Mycobacterium tuberculosis-activated p38 MAPK via inhibition of AP-1 binding.

Authors:  Jidong Zhang; Xuesong Qian; Huan Ning; Christopher S Eickhoff; Daniel F Hoft; Jianguo Liu
Journal:  J Immunol       Date:  2011-04-11       Impact factor: 5.422

Review 9.  IL-27-induced modulation of autoimmunity and its therapeutic potential.

Authors:  Rakeshchandra R Meka; Shivaprasad H Venkatesha; Steven Dudics; Bodhraj Acharya; Kamal D Moudgil
Journal:  Autoimmun Rev       Date:  2015-08-05       Impact factor: 9.754

10.  IL27: its roles in the induction and inhibition of inflammation.

Authors:  Joseph W Carl; Xue-Feng Bai
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.